🎙️ In a recent OncLive On Air podcast, David Morris, MD, FACS, and Alan Bryce, MD, discuss the FDA approval of rucaparib for patients with BRCA mutation–associated mCRPC.
🔗 Listen to the podcast: www.onclive.com/view/fda-app...
#ProstateCancer #mCRPC #PARPInhibitors #PrecisionOncology #Oncology

Replicative gaps in DNA damage tolerance, genome instability, and cancer therapy Replicative single-stranded DNA gaps arise when DNA synthesis proceeds past lesions or difficult-to-replicate regions. This review delineates the pathways that generate, stabilize, and process these i...

Excited to share our new review in Molecular Cell on replicative single-stranded DNA gaps and their role in genome instability and cancer therapy.

#DNARepair #ReplicationStress #GenomeStability #CancerResearch #MolecularBiology #PARPinhibitors​​​​​​​​​​​​​​​​

www.cell.com/molecular-ce...

🧬 4 inhibidores clave de #PARP en el tratamiento del cáncer de próstata
💊 Terapia dirigida
🎯 Mutaciones #BRCA
🔗 Tratamientos combinados

#CáncerDePróstata #PARPInhibitors #MedicinaDePrecisión #PrecisionMedicine #TerapiaDirigida #TargetedTherapy #HRR #DNARepair #DengYueMedicinasEnHongKong

French consensus published in Ther Adv Med Onc-provide practical, real‑world guidance to prevent and manage hematologic toxicities from PARPis in metastatic PC-an area of growing need.
🔗 Full article: buff.ly/9fa08rG
#ProstateCancer #mCRPC #PARPInhibitors #Oncology

This study reveals the synergy between #Lansoprazole & #PARPinhibitors (PARPi) that suppresses BRCA1 expression in TNBC via #FASN inhibition, underscoring the #therapeutic potential of PARPi in #Tumors lacking #BRCA germline #Mutations. #medsky

#OpenAccess: www.sciencedirect.com/science/arti...

Tumor-associated neutrophil precursors impair homologous DNA repair and promote sensitivity to PARP inhibition - Nature Communications Tumor-associated neutrophils exhibit heterogeneity in breast cancer. Here, the authors identify a distinct precursor population (PreNeu) in estrogen receptor-positive tumors. PreNeu suppress homologou...

🚀 Excited to share our latest publication!
👉 www.nature.com/articles/s41...
A fantastic collaboration with an incredible team.

#BreastCancer #Neutrophils #TumorMicroenvironment #PARPinhibitors #DNARepair #NatureCommunications #CancerImmunology #CalcinottoLab

Expanding the Role of PARP Inhibitors: Emerging Strategies in BRCA+ and HRD+ Breast Cancer | Docwire News Dr. Gradishar reviews PARP data, new combos, and tools to better select breast cancer patients for targeted treatment.

🎧 New Podcast Episode
"Expanding the Role of PARP Inhibitors in BRCA+ & HRD+ Breast Cancer"
Dr. William Gradishar, @medillschool.bsky.social, breaks down key insights from #asco25.
🎙️ Listen now → docwirenews.com/podcast/expa... @ascocancer.bsky.social #BreastCancer #Oncology #PARPinhibitors #BRCA

New draft update protocol alert! 🚨 Our "PARP Inhibitors in the Management of Ovarian Cancer" is open for comments until July 21.

Share your feedback ➡️ brnw.ch/21wU0Vh
#OvarianCancer #PARPInhibitors

We’re excited to share a new pre-print from the lab! Led by Carmen Ramirez Moncayo and a fantastic collaboration with several groups from across @mrc-lms.bsky.social & @imperialcollegeldn.bsky.social. Interested in #OvarianCancer, #PARPinhibitors or #DrugDistribution? please read on! bit.ly/45lpekS

Understanding BRCAness: What It Means for Cancer Treatment BRCAness refers to tumors that mimic BRCA1/2 mutation behavior, making them vulnerable to DNA-damaging treatments like PARP inhibitors

Understanding BRCAness: What It Means for Cancer Treatment www.news-medical.net/health/Under... #BRCAness #CancerResearch #DNArepair #PrecisionOncology #PARPinhibitors #TargetedTherapy #Genomics #Oncology

A meta-analysis study looking at prior studies of #PARPinhibitors in those with metastatic castration-resistant #prostatecancer showed the greatest benefit in #BRCA carriers and no benefit in #ATM or #CHEK2 carriers. Learn more at ⤸
pubmed.ncbi.nlm.nih.gov/39848867/
@euplatinum.bsky.social

TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress Abstract. Oncogene activation in normal untransformed cells induces DNA replication stress and creates a dependency on DNA damage response (DDR) mechanisms

Oncogene activation causes #DNAreplicationstress, forcing cells to rely on #DNArepair. In #KRASdriven #PDAC, deletion of TRIP13 causes HR defects and cells become sensitive to #PARPinhibitors, making TRIP13 a new #therapeutictarget. Read the full article here: doi.org/10.1093/narc... #NARCancer

🧬 Don't miss the fourth and final session of NAR Cancer's 5th Anniversary Virtual Symposium!

🕛 Thursday 17 April at 12pm US Eastern time

👥 Speakers include Dr Elise Fouquerel and Dr Robert W. Sobol

Register here: lnkd.in/eRxxSxeu

#NARCancer #PARPInhibitors #DNARepair #GenomicStability

🧬 Don't miss the 4th session of NAR Cancer's 5th Anniversary Virtual Symposium!

🕛 Thursday 17 April - 12pm US Eastern time

👥 Featuring Dr Elise Fouquerel and Dr Robert W. Sobol

👉 Register here: lnkd.in/eRxxSxeu

#NARCancer #CancerResearch #DNADamage #DNARepair #GenomicStability #PARPInhibitors

PhD student Tao Xie from our group presenting her research at #ANZGOG2025ASM this week on discovering new ways to address acquired resistance to #PARPinhibitors in #OvarianCancer. A bustling poster session! #High-GradeSerousOvarianCancer #DrugResistance #olaparib #niraparib 🧪

Our research impact: PARP inhibitors To mark our outstanding success in REF2021, Alison Halliday spoke to several of our researchers here at the ICR who were instrumental in the development of PARP inhibitors, a type of targeted drug tha...

In this feature we explored our research into #PARPinhibitors like #olaparib, which are now used to treat some forms of #BreastCancer, #OvarianCancer and #ProstateCancer.

It's just one example of an ICR research programme that's changed the lives of cancer patients.

www.icr.ac.uk/news-feature...

The July Issue of @CellChemBiol is live! Read it here: http://dlvr.it/T9mKhz #smoothened #hedgehog #optogenetics #NaVs #Rho-GTPase #YAP1 #MesenchymalStemCells #K2Pchannels #PROTAC #deubiquitylase #chromatin #PARPinhibitors